Latest News About Revolution Medicines Inc

Here are the latest publicly reported updates on Revolution Medicines Inc as of now.

• Financial and pipeline updates (2024–2025): Revolution Medicines has been actively advancing its RAS(ON) inhibitor program, including RMC-6236 and related compounds, with filings and timelines shared in 2024–2025, and continued discussions with FDA about trial designs and potential registrational study plans.[1][4]
• Key corporate developments (2025–2026): In 2025, Revolution Medicines announced a $2 billion flexible funding agreement with Royalty Pharma to support development and potential commercialization of its RAS(ON) portfolio, signaling strong financial backing for late-stage efforts. They also disclosed ongoing Phase 3 trials for daraxonrasib and related programs, highlighting progress toward potential pivotal data readouts.[3]
• Recent trading and market signals (early 2026): Market reports in early 2026 noted stock activity and coverage around the company, including premarket moves tied to broader investor interest and media reports, though exact figures vary by day.[8][10]
• Earnings context (2025): Revolution Medicines reported quarterly results in 2025 reflecting ongoing development costs and RAS(ON) program activities, with a net loss typical for a late-stage biotech near pivotal data milestones.[6]

If you’d like, I can pull the most recent press releases or summarize the latest quarterly earnings in a concise timeline, or set up a quick table comparing RMC-6236, RMC-9805, and other RAS(ON) assets with their current development stage and trial names.

Would you prefer a focused update on the clinical pipeline, corporate financing, or stock-market activity?

Cited sources: Revolution Medicines press releases and coverage from 2024–2025 across Yahoo Finance, GlobeNewswire, and Market/Stock news outlets.[4][10][1][3][6][8]